General information, not medical advice. Sea moss contains iodine. Ask your GP before use if you have a thyroid condition, take medication, or are pregnant or breastfeeding. Quality & Testing.
## Introduction
The most common objection we hear from gut-recovery customers is sharp and reasonable: *"I have SIBO. Won't this fibre make my bloating worse?"* The honest answer is that it depends on your breath-test phenotype, your current treatment phase, the molecular weight of the carrageenan you are ingesting, and how the dose is timed against your prokinetic. Generic "is sea moss good for SIBO" advice is clinically meaningless because SIBO is not one condition.
Small intestinal bacterial overgrowth is a heterogeneous diagnosis. The 2020 American College of Gastroenterology clinical guideline formally separated bacterial overgrowth from intestinal methanogen overgrowth (IMO), because methanogens such as *Methanobrevibacter smithii* are archaea a different domain of life and they behave differently from hydrogen-producing bacteria (Pimentel et al., 2020). Hydrogen-dominant overgrowth tends toward loose stools; methane-dominant IMO tends toward constipation, because methane gas itself slows intestinal transit by an average of 59% in canine infusion models (Pimentel et al., 2006). A fermentable, viscous, mineral-dense substrate like *Chondrus crispus* gel will land differently across these two phenotypes.
This article does not tell you whether to take sea moss. It gives you the decision tree your gastroenterologist or naturopath would use, the breath-test cut-offs that define each phenotype, the pharmacological reasoning for timing around rifaximin and prokinetics, and a three-stage reintroduction protocol that practitioners can actually defend. If you have not yet read our broader gut overview, start with [Sea Moss and the Gut](/blogs/learn/benefits/sea-moss-gut-health) and then return here.
## Why "fibre is good for the gut" is the wrong frame in SIBO
The popular wellness rule *more fibre, better gut* is derived from large-bowel epidemiology in healthy populations. In SIBO it is structurally wrong. The problem in SIBO is not that the colon has too few fermenters; it is that the small intestine has too many. Soluble fermentable fibre that would normally pass through the small bowel intact and be metabolised in the cecum and proximal colon is instead intercepted upstream, where the small intestine is narrow, richly innervated, and not designed for gas production.
Even in irritable bowel syndrome without confirmed overgrowth, the fibre data is more nuanced than wellness shorthand suggests. The 2014 systematic review and meta-analysis by Moayyedi and colleagues found that **soluble fibre is effective in treating IBS** with a relative risk of 0.83 and a number needed to treat of 7, while bran (insoluble fibre) showed no benefit and sometimes worsened symptoms (Moayyedi et al., 2014). The clinical lesson is that fibre *type* matters more than fibre *quantity* and in SIBO specifically, timing, viscosity, and fermentation site dominate the equation.
Sea moss is a viscous soluble fibre. The carrageenan polysaccharides roughly 55% of the dry weight of *Chondrus crispus* are not cleaved by human glycoside hydrolases and reach the colon largely intact in a healthy gut, where specific Bacteroidetes such as *Bacteroides xylanisolvens* depolymerise them via β-carrageenase activity (Li et al., 2017). In an untreated SIBO small intestine, however, that orderly colonic fermentation gets short-circuited.
## The four SIBO phenotypes and how sea moss interacts with each
The 2017 North American Consensus on breath testing standardised the diagnostic cut-offs that define each phenotype (Rezaie et al., 2017):
| Phenotype | Breath test signature | Typical bowel pattern | Sea moss risk profile |
| --- | --- | --- | --- |
| Hydrogen-dominant SIBO | H2 rise greater than or equal to 20 ppm by 90 min | Loose stools, urgency, post-meal gas | High during active phase premature fermentation and viscosity-driven distension |
| Methane-dominant IMO | CH4 greater than or equal to 10 ppm at any point | Constipation, hard stools, abdominal fullness | High methane slowing of transit amplifies fibre stasis (Pimentel et al., 2006) |
| Mixed (H2 + CH4) | Both thresholds met | Alternating IBS-M pattern | High both fermentation pathways present |
| Hydrogen sulphide (suspected) | Flat hydrogen with sulphurous symptoms | Diarrhoea, rotten-egg gas | Moderate sulphate-reducing pathways are not directly fed by carrageenan but data is sparse |
The clinical principle is simple: **any phenotype with an active breath-positive overgrowth is a contraindication to high-dose viscous soluble fibre, including sea moss gel, until the overgrowth is treated**. This is not a brand-positioning statement it is a structural feature of how the small intestine handles fermentable substrate.
### Hydrogen-dominant SIBO
Within 30 to 90 minutes of a 1 tablespoon gel serving, untreated hydrogen-dominant SIBO patients typically report upper-abdominal distension, audible borborygmi, and a sensation of pressure under the lower ribs. The mechanism is straightforward: fermentable galactans hitting overgrowth populations in the duodenum and jejunum, where stretch receptors fire fast. Viscosity compounds the problem by delaying gastric emptying, so the fibre dwells longer in the upper bowel.
### Methane-dominant IMO
Methane-dominant patients face a different problem. Pimentel and colleagues demonstrated in dog small-intestinal infusion experiments that methane gas itself slows transit by an average of 59% and augments segmental contractile activity rather than propulsive activity (Pimentel et al., 2006). Adding a viscous, water-binding fibre on top of methane-mediated motility suppression frequently produces a worsening of constipation, hardened stool, and a paradoxical sense of "everything has stopped." This is not a sea moss allergy; it is gas-mediated dysmotility plus a viscous bulking agent in a sluggish lumen.
### Mixed and hydrogen sulphide phenotypes
Mixed phenotypes show both fermentation patterns and tend to fail single-class trials. Hydrogen sulphide overgrowth still emerging as a formal diagnostic category is suggested by flat hydrogen curves, sulphurous belching, and diarrhoea. There is no published evidence that sea moss specifically fuels sulphate-reducing bacteria, but the prudent default is to defer reintroduction until breath testing is unambiguously negative.
## Rifaximin, prokinetics, and the timing windows that matter
Once a SIBO phenotype is confirmed, treatment generally combines a gut-restricted antibiotic most commonly **rifaximin 550 mg three times daily for 14 days** (Pimentel et al., 2020) with a maintenance prokinetic to support the migrating motor complex (MMC) between meals. Both intersect with how and when you reintroduce sea moss.
### Rifaximin is gut-restricted, and food (or fibre) does not change that
The XIFAXAN (rifaximin) FDA prescribing information is explicit: rifaximin is minimally absorbed, with greater than 96% of an oral dose recovered unchanged in faeces, and **may be administered with or without food** (Salix Pharmaceuticals, 2017). A high-fat meal increases systemic exposure approximately two-fold, but systemic exposure is not the relevant pharmacological endpoint the drug works in the lumen. There is no FDA-label evidence that viscous soluble fibre meaningfully changes rifaximin efficacy.
> "Of the 96.94% total recovery, 96.62% of the administered radioactivity was recovered in feces mostly as the unchanged drug."
> XIFAXAN Prescribing Information (Salix Pharmaceuticals, 2017)
That said, most practitioners and we agree recommend **withholding sea moss during the 14-day rifaximin course** for a different reason: you want to minimise fermentable substrate during the eradication window so you can assess symptom resolution cleanly. This is a clinical-judgement call, not a pharmacokinetic mandate.
### Prokinetics need a fasted lumen separate them from sea moss
Maintenance prokinetics such as low-dose prucalopride, low-dose erythromycin, and ginger extracts work by reinforcing the MMC, the inter-digestive housekeeper wave that sweeps residual content and bacteria through the small bowel between meals. The MMC only runs when no calories are arriving. Practitioners generally dose prokinetics at bedtime, at least 3 to 4 hours after the last food intake.
Because sea moss gel is calorically negligible but mucilaginous and slow to clear, the conservative protocol is to **separate sea moss from any prokinetic by 60 to 90 minutes** to preserve the fasted MMC window. Take prokinetics on an empty stomach at bedtime; take sea moss gel with morning or midday food, not within 90 minutes of a prokinetic dose.
## A decision checkpoint you can actually self-apply
Before reintroducing sea moss after SIBO treatment, work through this checklist with your practitioner. Tick every box before progressing to Stage 1 of the reintroduction protocol below.
- [ ] I have completed a glucose or lactulose breath test within the last 6 weeks and know my hydrogen and methane curves
- [ ] I have either completed a full course of rifaximin (or equivalent), an elemental diet, or a documented dietary clearance phase
- [ ] My most recent post-treatment breath test shows H2 less than 20 ppm rise by 90 min and CH4 less than 10 ppm at all timepoints, OR my symptoms have improved substantially and my prescriber is supportive of a reintroduction trial
- [ ] I am not currently taking warfarin without INR monitoring, an ACE inhibitor without potassium monitoring, or metformin without timing adjustment (see [Sea Moss and Blood Thinners](/blogs/learn/science-safety/blood-thinners-interactions))
- [ ] I have a current thyroid panel (TSH, free T4) and have read [Iodine and Thyroid Safety](/blogs/learn/science-safety/iodine-thyroid-safety) for my lot's per-serving iodine math
- [ ] I have a Bristol Stool diary ready to log Type 1 through 7 daily for the first 14 days
- [ ] My batch has a published lot-level COA with ICP-MS heavy metals and HPLC-ICP-MS arsenic speciation, plus a measured iodine value in mcg/g
If any box is unchecked, the answer is *not yet*. Resolve that item first.
## The three-stage reintroduction protocol
This protocol is designed for adults who have completed SIBO treatment and ticked every box above. It is conservative by design the cost of pushing too fast is a 48-hour flare; the cost of going slow is one extra week.
### Stage 1 Sub-threshold priming (days 1 to 7)
- **Dose:** 2 to 3 mL of cold-prepared *Chondrus crispus* gel per day (roughly half a teaspoon), taken with the morning meal
- **Why this dose:** Below the typical fermentation threshold that triggers symptomatic distension, but enough to begin re-exposing colonic Bacteroidetes to carrageenan substrate
- **Watch for:** Any return of pre-treatment bloating within 30 to 90 minutes, Bristol Stool change of 2 or more points in either direction, or new abdominal pain
- **Decision rule:** If symptoms recur stop, reassess for incomplete eradication, and consult your prescriber. If asymptomatic for 7 consecutive days proceed to Stage 2.
### Stage 2 Functional dose escalation (days 8 to 21)
- **Dose:** 1 teaspoon (approximately 5 mL) of gel per day, increasing to 1 tablespoon (15 mL) by day 21 if tolerated
- **Timing:** With food, at least 60 to 90 minutes away from any prokinetic dose and at least 2 hours away from levothyroxine if you take it
- **Watch for:** Bristol Stool Type 6 or 7 this signals osmotic overload, not failure. The correct response is to **halve the dose for 3 days**, then resume escalation, rather than discontinue.
- **Decision rule:** Stable Bristol Stool Type 3 to 5 with no upper-abdominal distension for the full 14 days → proceed to Stage 3.
### Stage 3 Maintenance (day 22 onward)
- **Dose:** 1 to 2 tablespoons of gel per day, or equivalent capsule dose, with a one-day-per-week pause to allow MMC reset and reduce iodine accumulation
- **Re-test:** Repeat breath test at 3 months if symptoms creep back; otherwise annually
- **Iodine ceiling:** Even at maintenance, verify per-serving iodine from your lot COA so you stay well below the 1,100 mcg/day adult tolerable upper intake level set by the NHMRC and FSANZ (NHMRC, 2006)
## Why the carrageenan question is not the same as the SIBO question
Customers sometimes conflate two distinct concerns: *carrageenan-mediated gut inflammation* and *SIBO bloating*. They are different mechanisms and the evidence base for each is separate.
The carrageenan-inflammation literature distinguishes **native high-molecular-weight carrageenan** (greater than 100 kDa, present in food and our cold-process gel) from **poligeenan** (also called degraded carrageenan, low molecular weight, produced industrially via acid hydrolysis at low pH and high temperature). The conditions that produce poligeenan are absent in both our small-batch preparation and in the human stomach. In vitro studies do show that very low molecular weight kappa-carrageenan oligosaccharides around 4.5 kDa can be degraded by human gut microbiota and produce pro-inflammatory signalling on epithelial cells, while higher molecular weight forms (450 kDa) largely cannot (Li et al., 2017). The dietary form in our gel sits at the high end of that spectrum.
SIBO bloating, by contrast, is a mechanical and gas-physics problem in the wrong anatomical compartment. Even an immaculate native carrageenan will cause distension in an untreated overgrowth, because the issue is not the molecule it is that the molecule is being fermented in the wrong part of the gut.
## Why species, lot, and method actually matter in this conversation
A practitioner reintroducing fibre into a recently-eradicated SIBO patient needs to know exactly what they are reintroducing. This is where the brand-level decisions translate into clinical confidence:
- **Species verification.** The commercial term *sea moss* covers *Chondrus crispus*, *Gracilaria* spp., and *Eucheuma cottonii* three species with different polysaccharide profiles. *Eucheuma cottonii* is rich in kappa-carrageenan; *Gracilaria* yields agar; *Chondrus crispus* contains a kappa-lambda mixture. SeaMossVibes publishes species declaration on every lot COA.
- **Per-lot ICP-MS plus HPLC-ICP-MS arsenic speciation.** Sea moss bioaccumulates arsenic, lead, cadmium, and mercury. Inorganic arsenic is the regulated toxic fraction (Prop 65 reference under 10 mcg/day). A single legacy test reused across 18 months of production is not the same thing as per-batch verification.
- **Measured iodine in mcg/g.** A 45 g serving of dried *Chondrus crispus* can deliver up to 2,100 mcg of iodine nearly double the adult tolerable upper intake level of 1,100 mcg/day set by the NHMRC (NHMRC, 2006). Per-lot iodine values are the only way to compute your real per-serving exposure.
- **Cold-process preparation.** Avoids the high-temperature acid hydrolysis that produces poligeenan and preserves the native high-molecular-weight carrageenan that resists upper-GI fermentation in a healthy gut.
- **Adelaide-based AU cold-chain logistics.** Reduces transit-time microbial risk relative to multi-week international shipping of refrigerated gel.
These are the proof points your practitioner needs to put their name behind a reintroduction protocol and they are the points most AU competitors cannot supply.
## When sea moss may NOT be appropriate
Skip sea moss entirely, or defer until the listed issue is resolved, if any of the following apply:
- Active hydrogen-dominant SIBO, methane-dominant IMO, or mixed overgrowth, breath-confirmed within the last 6 weeks and untreated
- Active diverticulitis flare or known small-bowel stricture
- Pregnancy or lactation without an endocrinologist-supervised iodine plan (the iodine load is the issue, not the fibre)
- Known thyroid disease (Hashimoto's, Graves', autonomous nodules) without endocrinology review see [Iodine and Thyroid Safety](/blogs/learn/science-safety/iodine-thyroid-safety)
- Current warfarin therapy without INR adjustment for the variable vitamin K load see [Blood Thinners and Sea Moss](/blogs/learn/science-safety/blood-thinners-interactions)
- ACE inhibitor or potassium-sparing diuretic therapy without serum potassium monitoring
- Recent abdominal surgery with ongoing motility recovery
**Always read the label and follow directions for use. This product is not intended to diagnose, treat, cure, or prevent any disease.** Consult your GP, gastroenterologist, or registered practitioner before introducing sea moss if you have any active gastrointestinal condition, thyroid disease, take anticoagulants, ACE inhibitors, metformin, or potassium-sparing diuretics, or are pregnant or breastfeeding.
## Conclusion: the same fibre can heal and harm phenotype decides
Sea moss is neither a SIBO cure nor a SIBO trigger. It is a fermentable viscous soluble fibre whose effect depends entirely on the state of the lumen it enters. In an untreated hydrogen- or methane-dominant overgrowth, a daily tablespoon of gel will reliably produce premature small-bowel fermentation and 30 to 90 minute distension. In a post-treatment gut with normalised breath tests, the same dose graded in over three stages typically supports colonic short-chain fatty acid production without recurrence.
The decision tree is not glamorous, but it is honest: confirm the phenotype, complete the treatment, time the reintroduction around prokinetics and rifaximin, and watch the Bristol diary. Sea moss is a tool for the second half of SIBO recovery, not the first. Brands that tell you otherwise are selling adjectives.
Sea moss is a bioaccumulator of arsenic, lead, cadmium, and mercury. Choose a supplier that publishes batch-level ICP-MS results with HPLC-ICP-MS arsenic speciation. SeaMossVibes publishes a COA per lot. The adult tolerable upper intake level (UL) for iodine is 1,100 mcg/day always check the per-serving iodine on your batch COA.
## Next step
[Take the Mineral Blueprint](/vitality/assessment) to map your current gut phenotype, medication list, and goals to a 14-day starter protocol including the cold-hydration timing windows discussed above and your batch's measured iodine value.
## References
- Li, M., Shang, Q., Li, G., Wang, X., & Yu, G. (2017). Degradation of marine algae-derived carbohydrates by Bacteroidetes isolated from human gut microbiota. *Marine Drugs*, 15(4), 92. https://pmc.ncbi.nlm.nih.gov/articles/PMC5408238/
- Moayyedi, P., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Ford, A. C. (2014). The effect of fiber supplementation on irritable bowel syndrome: A systematic review and meta-analysis. *American Journal of Gastroenterology*, 109(9), 1367 1374. https://pubmed.ncbi.nlm.nih.gov/25070054/
- National Health and Medical Research Council. (2006). *Nutrient Reference Values for Australia and New Zealand including Recommended Dietary Intakes*. NHMRC and New Zealand Ministry of Health. https://www.nhmrc.gov.au/about-us/publications/nutrient-reference-values-australia-and-new-zealand-including-recommended-dietary-intakes
- Pimentel, M., Lin, H. C., Enayati, P., van den Burg, B., Lee, H.-R., Chen, J. H., Park, S., Kong, Y., & Conklin, J. (2006). Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. *American Journal of Physiology Gastrointestinal and Liver Physiology*, 290(6), G1089 G1095. https://pubmed.ncbi.nlm.nih.gov/16293652/
- Pimentel, M., Saad, R. J., Long, M. D., & Rao, S. S. C. (2020). ACG clinical guideline: Small intestinal bacterial overgrowth. *American Journal of Gastroenterology*, 115(2), 165 178. https://journals.lww.com/ajg/fulltext/2020/02000/acg_clinical_guideline__small_intestinal_bacterial.9.aspx
- Rezaie, A., Buresi, M., Lembo, A., Lin, H., McCallum, R., Rao, S., Schmulson, M., Valdovinos, M., Zakko, S., & Pimentel, M. (2017). Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. *American Journal of Gastroenterology*, 112(5), 775 784. https://pubmed.ncbi.nlm.nih.gov/28323273/
- Salix Pharmaceuticals. (2017). *XIFAXAN (rifaximin) tablets, for oral use prescribing information*. U.S. Food and Drug Administration. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=523f0320-cc73-445a-a48d-7a181c182307&type=display
Ready to start?
Turn what you learned into a daily ritual
Explore formats and product details, then check the physical label before use.
Explore products →
Listed ingredients · Storage guidance


